One time a day mometasone/indacaterol fixed-dose combination versus two times a day fluticasone/salmeterol in patients with inadequately controlled asthma: pooled analysis from PALLADIUM and IRIDIUM studies

• Huib A M Kerstjens,
• Motoi Hosoe,
• Yasuhiro Gon,
• Kenneth Chapman,
• Ana-Maria Tanase,
• Richard van Zyl-Smit,
• Jorge Maspero,
• Abhijit Pethe,
• Xu Shu,
• Peter D’Andrea

Affiliations

Huib A M Kerstjens

Department of Pulmonology, University of Groningen, University Medical Center Groningen, and Groningen Research Institute for Asthma and COPD, Groningen, The Netherlands

Motoi Hosoe

Novartis Pharma AG, Basel, Switzerland

Yasuhiro Gon

Division of Respiratory Medicine, Department of Internal Medicine, Nihon University School of Medicine, Tokyo, Japan

Kenneth Chapman

Division of Respiratory Medicine, Department of Medicine, University of Toronto, Toronto, Ontario, Canada

Ana-Maria Tanase

Novartis Pharma AG, Basel, Switzerland

Richard van Zyl-Smit

Division of Pulmonology and UCT Lung Institute, Department of Medicine, University of Cape Town, Cape Town, South Africa

Jorge Maspero

Allergy and Respiratory Research Unit, Fundación Centro Investigacion de Enfermedades Alergicas y Respiratorias, Buenos Aires, Argentina

Abhijit Pethe

Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA

Xu Shu

Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA

Peter D’Andrea

Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA